Head-to-head · WeighScore
Aurelius Health Group vs Lean Rx
The verdict
Aurelius Health Group takes it — 60.8/100 to 60.6/100, but only just.
Aurelius Health Group grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Aurelius Health Group is a telehealth platform built around compounded tirzepatide microdosing — a low-dose dual GIP/GLP-1 protocol rather than standard full-dose therapy — with optional NAD+, L-carnitine,… Lean Rx is close behind and may still be the better fit — see the factor split below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Aurelius Health Group | Lean Rx |
|---|---|---|
| WeighScore | 60.8/100 | 60.6/100 |
| Grade | C | C |
| Scorecard rank | #311 | #318 |
| Semaglutide | Not disclosed | $266/mo (starting dose, compounded) |
| Tirzepatide | $199/mo (microdose tier, compounded) | $399/mo (starting dose, compounded) |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Yes |
Graded #311 · C
Strengths
- Pricing fully published and bundled: $89 first month, then $199/mo all-in — more transparent than most compounded brands
- LegitScript Certified
- Care-inclusive model: consults, monthly monitoring, and secure messaging rather than Rx-only
- Unusually candid about the limited evidence base for microdosing
Where it loses points
- The advertised $89 is a first-month new-patient rate; every month after it is $199
- This is a 1 mg microdose programme and nothing else — no labelled therapeutic dose is sold, so it is not an alternative to a full-dose prescription
- No state count is published, only 'most US states', confirmed at intake
- The site's own comparison table calls 2.4 mg/week the tirzepatide 'standard full dose'; 2.4 mg is the semaglutide maintenance dose, and tirzepatide is labelled 2.5-15 mg/week
- Compounded tirzepatide is not an FDA-approved finished product
Graded #318 · C
Strengths
- Both semaglutide and tirzepatide offered
- Three formulations: injectable, sublingual, and tablet
- Upfront pricing with no hidden fees advertised
- Semaglutide starts at a low $266/month
- Telehealth call with a licensed provider before prescribing
Where it loses points
- Compounded-only; no FDA-approved branded options
- No published state availability list
- Platform is technology only, not a healthcare provider itself
- Provider credentials not detailed on site
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.